Levamlodipine
- Generic Name
- Levamlodipine
- Brand Names
- Conjupri
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 103129-82-4
- Unique Ingredient Identifier
- 0P6NLP6806
- Background
Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity.
Levamlodipine was granted FDA approval on 19 December 2019.
- Indication
Levamlodipine is indicated alone or in combination to treat hypertension in adults and children.
- Associated Conditions
- Hypertension
Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: TELMINUVO Tab. (80/2.5mg)Drug: TELMINUVO Tab. (80/5mg)
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 200
- Registration Number
- NCT01983735
- Locations
- 🇰🇷
The catholic university of Korea Seoul St. Mary's hospital, Seoul, Korea, Republic of
Efficacy and Safety of CKD-828 to Stage 2 Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: CKD-828 2.5/40mgDrug: CKD-828 5/40mgDrug: CKD-828 5/80mg
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 103
- Registration Number
- NCT01634295
- Locations
- 🇰🇷
Seoul national university Bundang Hospital, Bundang-gu, Gyeonggi-do, Korea, Republic of
CKD-828 S-Amlodipine Non-Responder Trial
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 187
- Registration Number
- NCT01501253
- Locations
- 🇰🇷
Seoul St. Mary's hospital, The catholic university of Korea, Seoul, Korea, Republic of
CKD-828 Drug Interaction Study (S-amlodipine)
- Conditions
- Healthy Male Volunteers
- Interventions
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT01356043
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2010-05-27
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1080
- Registration Number
- NCT01131546
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
CKD-828 Primary Hypertension Trial(Dose-selection)
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 430
- Registration Number
- NCT01128322
- Locations
- 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷Korea University Guro Hospital, Seoul, Korea, Republic of
🇰🇷DonGuk University International Hospital, Goyang, Korea, Republic of
Efficacy and Safety Study of S-Amlodipine Gentisate Compared to Amlodipine Besylate to Treat Mild-to-Moderate Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2007-03-06
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT00289406
- Locations
- 🇰🇷
SKChemicals, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.